diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/DM12784diaendo-12784Research ArticleОбзорыReviewРоль конечных продуктов гликирования в патогенезе диабетической нефропатииThe role of advanced glycation end products in patogenesis of diabetic nephropathyhttps://orcid.org/0000-0001-8148-8180ГавриловаА. О.GavrilovaA. O.

Гаврилова Алина Олеговна – аспирант; eLibrary SPIN: 8814-0121.

117036, Москва, ул. Дм. Ульянова, д. 11

Alina O. Gavrilova, PhD student; eLibrary SPIN: 8814-0121.

11 Dm. Ulyanova street, 117036 Moscow

a.o.gavrilova@list.ruhttps://orcid.org/0000-0002-0296-4933СеверинаА. С.SeverinaA. S.

Северина Анастасия Сергеевна - кандидат медицинских наук, ведущий научный сотрудник; eLibrary SPIN: 3182-9510.

Москва

Anastasia S. Severina - MD, PhD, senior research associate; eLibrary SPIN: 3182-9510

Moscow

ansev1@mail.ruhttps://orcid.org/0000-0002-3433-0142ШамхаловаМ. Ш.ShamhalovaM. S.

Шамхалова Минара Шамхаловна - доктор медицинских наук; eLibrary SPIN: 4942-5481

Москва

Minara S. Shamhalova - MD, PhD; eLibrary SPIN: 4942-5481

Moscow

shamkhalova@mail.ruhttps://orcid.org/0000-0002-5057-127XШестаковаМ. В.ShestakovaM. V.

Шестакова Марина Владимировна - доктор медицинских наук, профессор, академик РАН; eLibrary SPIN: 7584-7015

Москва

Marina V. Shestakova - MD, PhD, Professor; eLibrary SPIN: 7584-7015

Moscow

nephro@endocrincentr.ruНациональный медицинский исследовательский центр эндокринологииРоссияEndocrinology Research CentreRussian Federation202104012022245461469Copyright © Гаврилова А.О., Северина А.С., Шамхалова М.Ш., Шестакова М.В., 20222022Гаврилова А.О., Северина А.С., Шамхалова М.Ш., Шестакова М.В.Gavrilova A.O., Severina A.S., Shamhalova M.S., Shestakova M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/12784

Сахарный диабет (СД) и хроническая болезнь почек — заболевания, которые по темпам прироста распространенности превысили эпидемические пороги во всех странах мира, что позволило отнести их к неинфекционным эпидемиям XXI в. Диабетическая нефропатия (ДН) ассоциирована с высокой инвалидизацией и смертностью пациентов. Ключевая роль в развитии и прогрессировании ДН принадлежит конечным продуктам гликирования (advanced glycation end products, AGE). Помимо того, что повышенное образование AGE обусловлено гипергликемией в условиях СД, при ДН прогрессивное снижение скорости клубочковой фильтрации, способствующее замедлению их выведения, и активация окислительного стресса служат дополнительными факторами усиления образования и накопления AGE в организме. Как непосредственное воздействие AGE, так и результат взаимодействия AGE с его клеточным рецептором — RAGE запускают каскад событий, способствующих дальнейшему прогрессированию ДН. В связи с чем несомненный интерес представляет поиск новых терапевтических стратегий, направленных на систему AGE-RAGE с целью замедления прогрессирования ДН при СД и улучшения прогноза данных пациентов.

Diabetes mellitus (DM) and chronic kidney disease are the diseases that have exceeded epidemic thresholds in terms of prevalence all over the world. That made it possible to classify them as non-communicable epidemics of the XXI century. Diabetic nephropathy (DN) is implicated with high levels of disablement and mortality. Advanced glycation end products (AGE) play a key role in the progression of DN. Increased formation of AGE occurs due to hyperglycemia under the conditions of diabetes. Moreover, there are additional factors in DN that increase the elaboration of AGE, such as high levels of oxidative stress and decreased renal clearance which slows down the AGE excretion. Both immediate effects of AGE and interaction of AGE with its cell-bound receptor (RAGE) result in a сascade of events that lead to further progression of DN. Thus, the research of the new therapeutic approaches targeted on the AGE-RAGE system is of great interest to slow progression of DN and improve the prognosis.

конечные продукты гликированияметаболическая памятьдиабетическая нефропатиясахарный диабетadvanced glycation end productsmetabolic memorydiabetic nephropathydiabetes mellitusРабота проведена в рамках выполнения Государственного задания Минздрава России (АААА-А20-120011790181-1)ReferencesKumar Pasupulati A, Chitra PS, Reddy GB. Advanced glycation end products mediated cellular and molecular events in the pathology of diabetic nephropathy. Biomol Concepts. 2016 Dec 1;7(5-6):293-309. doi: 10.1515/bmc-2016-0021.Kumar Pasupulati A, Chitra PS, Reddy GB. Advanced glycation end products mediated cellular and molecular events in the pathology of diabetic nephropathy. Biomol Concepts. 2016;7(5-6):293-309. doi: https://doi.org/10.1515/bmc-2016-0021Bettiga A, Fiorio F, Di Marco F, et al. The Modern Western Diet Rich in Advanced Glycation End-Products (AGEs): An Overview of Its Impact on Obesity and Early Progression of Renal Pathology. Nutrients. 2019 Jul 30;11(8):1748. doi: 10.3390/nu11081748.Bettiga A, Fiorio F, Di Marco F, et al. The Modern Western Diet Rich in Advanced Glycation End-Products (AGEs): An Overview of Its Impact on Obesity and Early Progression of Renal Pathology. Nutrients. 2019;11(8):1748. doi: https://doi.org/10.3390/nu11081748Bucala R, Cerami A. Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol. 1992;23:1-34. doi: 10.1016/s1054-3589(08)60961-8.Bucala R, Cerami A. Advanced glycosylation: chemistry, biology, and implications for diabetes and aging. Adv Pharmacol. 1992;23:1-34. doi: https://doi.org/10.1016/s1054-3589(08)60961-8Miyata T, Ueda Y, Yamada Y, et al. Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: carbonyl stress in uremia. J Am Soc Nephrol. 1998 Dec;9(12):2349-56. doi: 10.1681/ASN.V9122349.Miyata T, Ueda Y, Yamada Y, et al. Accumulation of carbonyls accelerates the formation of pentosidine, an advanced glycation end product: carbonyl stress in uremia. J Am Soc Nephrol. 1998;9(12):2349-56. doi: https://doi.org/10.1681/ASN.V9122349Maillard L: Action of amino acids on sugars. Formation of melanoidins in a methodical way. Compt Rend 154: 66–68, 1912.Maillard L. Action of amino acids on sugars. Formation of melanoidins in a methodical way. Compt Rend. 1912;154:66-68.Monnier VM, Nagaraj RH, Portero-Otin M, et al. Structure of advanced Maillard reaction products and their pathological role. Nephrol Dial Transplant. 1996;11 Suppl 5:20-6. doi: 10.1093/ndt/11.supp5.20.Monnier VM, Nagaraj RH, Portero-Otin M, et al. Structure of advanced Maillard reaction products and their pathological role. Nephrol Dial Transplant. 1996;11 Suppl 5:20-6. doi: https://doi.org/10.1093/ndt/11.supp5.20Wolff SP, Dean RT. Glucose autoxidation and protein modification. The potential role of 'autoxidative glycosylation' in diabetes. Biochem J. 1987 Jul 1;245(1):243-50. doi: 10.1042/bj2450243.Wolff SP, Dean RT. Glucose autoxidation and protein modification. The potential role of ‘autoxidative glycosylation’ in diabetes. Biochem J. 1987;245(1):243-50. doi: https://doi.org/10.1042/bj2450243Namiki M. Chemistry of Maillard reactions: recent studies on the browning reaction mechanism and the development of antioxidants and mutagens. Adv Food Res. 1988;32:115-84. doi: 10.1016/s0065-2628(08)60287-6.Namiki M. Chemistry of Maillard reactions: recent studies on the browning reaction mechanism and the development of antioxidants and mutagens. Adv Food Res. 1988;32:115-84. doi: https://doi.org/10.1016/s0065-2628(08)60287-6Hodge JE, Rist CE. The Amadori Rearrangement under New Conditions and its Significance for Non-enzymatic Browning Reactions2. J Am Chem Soc 1953; 75: 316-22. Nutrients 2010; 2: 1247–65. doi: 10.1021/ja01098a019Hodge JE, Rist CE. The Amadori Rearrangement under New Conditions and its Significance for Non-enzymatic Browning Reactions2. J Am Chem Soc 1953; 75: 316-22. Nutrients. 2010;2:1247-1265. doi: https://doi.org/10.1021/ja01098a019Piperi C, Adamopoulos C, Dalagiorgou G, et al. Crosstalk between advanced glycation and endoplasmic reticulum stress: emerging therapeutic targeting for metabolic diseases. J Clin Endocrinol Metab. 2012 Jul;97(7):2231-42. doi: 10.1210/jc.2011-3408. Epub 2012 Apr 16. PMID: 22508704.Piperi C, Adamopoulos C, Dalagiorgou G, et al. Crosstalk between advanced glycation and endoplasmic reticulum stress: emerging therapeutic targeting for metabolic diseases. J Clin Endocrinol Metab. 2012;97(7):2231-42. doi: https://doi.org/10.1210/jc.2011-3408Дедов И.И., Шестакова М.В. Феномен «метаболической памяти» в прогнозировании риска развития сосудистых осложнений при сахарном диабете. Терапевтический архив. 2015;10:4-10. doi: 10.17116/terarkh201587104-10Dedov II, Shestakova MV. The metabolic memory phenomenon in predicting a risk for vascular complications in diabetes mellitus. Terapevticheskii Arkhiv (Ter. Arkh.). (In Russ.). doi: https://doi.org/10.17116/terarkh201587104-10Bohlender JM, Franke S, Stein G, et al. Advanced glycation end products and the kidney. Am J Physiol Renal Physiol. 2005 Oct;289(4):F645-59. doi: 10.1152/ajprenal.00398.2004.Bohlender JM, Franke S, Stein G, et al. Advanced glycation end products and the kidney. Am J Physiol Renal Physiol. 2005;289(4):F645-59. doi: https://doi.org/10.1152/ajprenal.00398.2004Arsov S, Graaff R, van Oeveren W, et al. Advanced glycation end-products and skin autofluorescence in end-stage renal disease: a review. Clin Chem Lab Med. 2014 Jan 1;52(1):11-20. doi: 10.1515/cclm-2012-0832.Arsov S, Graaff R, van Oeveren W, et al. Advanced glycation end-products and skin autofluorescence in end-stage renal disease: a review. Clin Chem Lab Med. 2014;52(1):11-20. doi: https://doi.org/10.1515/cclm-2012-0832Kandarakis SA, Piperi C, Topouzis F, et al. Emerging role of advanced glycation-end products (AGEs) in the pathobiology of eye diseases. Prog Retin Eye Res. 2014 Sep;42:85-102. doi: 10.1016/j.preteyeres.2014.05.002.Kandarakis SA, Piperi C, Topouzis F, et al. Emerging role of advanced glycation-end products (AGEs) in the pathobiology of eye diseases. Prog Retin Eye Res. 2014;42:85-102. doi: https://doi.org/10.1016/j.preteyeres.2014.05.002Forbes JM, Yee LT, Thallas V, et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes. 2004 Jul;53(7):1813-23. doi: 10.2337/diabetes.53.7.1813.Forbes JM, Yee LT, Thallas V, et al. Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. Diabetes. 2004;53(7):1813-23. doi: https://doi.org/10.2337/diabetes.53.7.1813Yamamoto Y, Doi T, Kato I, et al. Receptor for advanced glycation end products is a promising target of diabetic nephropathy. Ann N Y Acad Sci. 2005 Jun;1043:562-6. doi: 10.1196/annals.1333.064.Yamamoto Y, Doi T, Kato I, et al. Receptor for advanced glycation end products is a promising target of diabetic nephropathy. Ann N Y Acad Sci. 2005;1043:562-6. doi: https://doi.org/10.1196/annals.1333.064Yamagishi S, Nakamura K, Inoue H, et al. Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer's disease. Med Hypotheses. 2005;64(6):1205-7. doi: 10.1016/j.mehy.2005.01.016.Yamagishi S, Nakamura K, Inoue H, et al. Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer’s disease. Med Hypotheses. 2005;64(6):1205-7. doi: https://doi.org/10.1016/j.mehy.2005.01.016Angeloni C, Zambonin L, Hrelia S. Role of methylglyoxal in Alzheimer's disease. Biomed Res Int. 2014;2014:238485. doi: 10.1155/2014/238485.Angeloni C, Zambonin L, Hrelia S. Role of methylglyoxal in Alzheimer’s disease. Biomed Res Int. 2014;2014:238485. doi: https://doi.org/10.1155/2014/238485Chilelli NC, Burlina S, Lapolla A. AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: a "glycoxidation-centric" point of view. Nutr Metab Cardiovasc Dis. 2013 Oct;23(10):913-9. doi: 10.1016/j.numecd.2013.04.004.Chilelli NC, Burlina S, Lapolla A. AGEs, rather than hyperglycemia, are responsible for microvascular complications in diabetes: a «glycoxidation-centric» point of view. Nutr Metab Cardiovasc Dis. 2013;23(10):913-9. doi: https://doi.org/10.1016/j.numecd.2013.04.004Makita Z, Radoff S, Rayfield EJ, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med. 1991 Sep 19;325(12):836-42. doi: 10.1056/NEJM199109193251202.Makita Z, Radoff S, Rayfield EJ, et al. Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med. 1991;325(12):836-42. doi: https://doi.org/10.1056/NEJM199109193251202Loughrey CM, Young IS, Lightbody JH, et al. Oxidative stress in haemodialysis. QJM. 1994 Nov;87(11):679-83. PMID: 7820542.Loughrey CM, Young IS, Lightbody JH, et al. Oxidative stress in haemodialysis. QJM. 1994;87(11):679-83. PMID: 7820542Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 1996 May;49(5):1304-13. doi: 10.1038/ki.1996.186.Witko-Sarsat V, Friedlander M, Capeillère-Blandin C, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 1996;49(5):1304-13. doi: https://doi.org/10.1038/ki.1996.186Dozio E, Vettoretti S, Caldiroli L, et al. Advanced Glycation End Products (AGE) and Soluble Forms of AGE Receptor: Emerging Role as Mortality Risk Factors in CKD. Biomedicines. 2020 Dec 21;8(12):638. doi: 10.3390/biomedicines8120638.Dozio E, Vettoretti S, Caldiroli L, et al. Advanced Glycation End Products (AGE) and Soluble Forms of AGE Receptor: Emerging Role as Mortality Risk Factors in CKD. Biomedicines. 2020;8(12):638. doi: https://doi.org/10.3390/biomedicines8120638Vlassara H, Striker LJ, Teichberg S, et al. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A. 1994 Nov 22;91(24):11704-8. doi: 10.1073/pnas.91.24.11704.Vlassara H, Striker LJ, Teichberg S, et al. Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci U S A. 1994;91(24):11704-8. doi: https://doi.org/10.1073/pnas.91.24.11704Yang CW, Vlassara H, Peten EP, et al. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9436-40. doi: 10.1073/pnas.91.20.9436.Yang CW, Vlassara H, Peten EP, et al. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci U S A. 1994;91(20):9436-40. doi: https://doi.org/10.1073/pnas.91.20.9436Tsilibary EC, Charonis AS, Reger LA, et al. The effect of nonenzymatic glucosylation on the binding of the main noncollagenous NC1 domain to type IV collagen. J Biol Chem. 1988 Mar 25;263(9):4302-8. PMID: 3346249.Tsilibary EC, Charonis AS, Reger LA, et al. The effect of nonenzymatic glucosylation on the binding of the main noncollagenous NC1 domain to type IV collagen. J Biol Chem. 1988;263(9):4302-8. PMID: 3346249Charonis AS, Reger LA, Dege JE, et al. Laminin alterations after in vitro nonenzymatic glycosylation. Diabetes. 1990 Jul;39(7):807-14. doi: 10.2337/diab.39.7.807. PMID: 2113013.Charonis AS, Reger LA, Dege JE, et al. Laminin alterations after in vitro nonenzymatic glycosylation. Diabetes. 1990;39(7):807-14. doi: https://doi.org/10.2337/diab.39.7.807. PMID: 2113013.Yamagishi S, Matsui T. Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longev. 2010 Mar-Apr;3(2):101-8. doi: 10.4161/oxim.3.2.11148.Yamagishi S, Matsui T. Advanced glycation end products, oxidative stress and diabetic nephropathy. Oxid Med Cell Longev. 2010;3(2):101-8. doi: https://doi.org/10.4161/oxim.3.2.11148Ziyadeh FN, Hoffman BB, Han DC, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8015-20. doi: 10.1073/pnas.120055097.Ziyadeh FN, Hoffman BB, Han DC, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A. 2000;97(14):8015-20. doi: https://doi.org/10.1073/pnas.120055097Silbiger S, Crowley S, Shan Z, et al. Nonenzymatic glycation of mesangial matrix and prolonged exposure of mesangial matrix to elevated glucose reduces collagen synthesis and proteoglycan charge. Kidney Int. 1993 Apr;43(4):853-64. doi: 10.1038/ki.1993.120.Silbiger S, Crowley S, Shan Z, et al. Nonenzymatic glycation of mesangial matrix and prolonged exposure of mesangial matrix to elevated glucose reduces collagen synthesis and proteoglycan charge. Kidney Int. 1993;43(4):853-64. doi: https://doi.org/10.1038/ki.1993.120Kushwaha K, Sharma S, Gupta J. Metabolic memory and diabetic nephropathy: Beneficial effects of natural epigenetic modifiers. Biochimie. 2020 Mar;170:140-151. doi: 10.1016/j.biochi.2020.01.007.Kushwaha K, Sharma S, Gupta J. Metabolic memory and diabetic nephropathy: Beneficial effects of natural epigenetic modifiers. Biochimie. 2020;170:140-151. doi: https://doi.org/10.1016/j.biochi.2020.01.007Genuth S, Sun W, Cleary P, et al. DCCT Skin Collagen Ancillary Study Group. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes. 2005 Nov;54(11):3103-11. doi: 10.2337/diabetes.54.11.3103.Genuth S, Sun W, Cleary P, et al. DCCT Skin Collagen Ancillary Study Group. Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with type 1 diabetes. Diabetes. 2005;54(11):3103-11. doi: https://doi.org/10.2337/diabetes.54.11.3103Ramasamy R, Yan SF, Schmidt AM. Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann N Y Acad Sci. 2011 Dec;1243:88-102. doi: 10.1111/j.1749-6632.2011.06320.x.Ramasamy R, Yan SF, Schmidt AM. Receptor for AGE (RAGE): signaling mechanisms in the pathogenesis of diabetes and its complications. Ann N Y Acad Sci. 2011;1243:88-102. doi: https://doi.org/10.1111/j.1749-6632.2011.06320.xFukami K, Taguchi K, Yamagishi S, et al. Receptor for advanced glycation endproducts and progressive kidney disease. Curr Opin Nephrol Hypertens. 2015 Jan;24(1):54-60. doi: 10.1097/MNH.0000000000000091.Fukami K, Taguchi K, Yamagishi S, et al. Receptor for advanced glycation endproducts and progressive kidney disease. Curr Opin Nephrol Hypertens. 2015;24(1):54-60. doi: https://doi.org/10.1097/MNH.0000000000000091Wautier MP, Chappey O, Corda S, et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab. 2001 May;280(5):E685-94. doi: 10.1152/ajpendo.2001.280.5.E685.Wautier MP, Chappey O, Corda S, et al. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab. 2001;280(5):E685-94. doi: https://doi.org/10.1152/ajpendo.2001.280.5.E685Hofmann MA, Drury S, Fu C, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999 Jun 25;97(7):889-901. doi: 10.1016/s0092-8674(00)80801-6.Hofmann MA, Drury S, Fu C, et al. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell. 1999;97(7):889-901. doi: https://doi.org/10.1016/s0092-8674(00)80801-6Yamamoto Y, Kato I, Doi T, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest. 2001 Jul;108(2):261-8. doi: 10.1172/JCI11771.Yamamoto Y, Kato I, Doi T, et al. Development and prevention of advanced diabetic nephropathy in RAGE-overexpressing mice. J Clin Invest. 2001;108(2):261-8. doi: https://doi.org/10.1172/JCI11771Shankland SJ. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int. 2006 Jun;69(12):2131-47. doi: 10.1038/sj.ki.5000410.Shankland SJ. The podocyte’s response to injury: role in proteinuria and glomerulosclerosis. Kidney Int. 2006;69(12):2131-47. doi: https://doi.org/10.1038/sj.ki.5000410Busch M, Franke S, Rüster C, et al. Advanced glycation end-products and the kidney. Eur J Clin Invest. 2010 Aug;40(8):742-55. doi: 10.1111/j.1365-2362.2010.02317.x.Busch M, Franke S, Rüster C, et al. Advanced glycation end-products and the kidney. Eur J Clin Invest. 2010;40(8):742-55. doi: https://doi.org/10.1111/j.1365-2362.2010.02317.xStriker LJ, Striker GE. Administration of AGEs in vivo induces extracellular matrix gene expression. Nephrol Dial Transplant. 1996;11 Suppl 5:62-5. doi: 10.1093/ndt/11.supp5.62.Striker LJ, Striker GE. Administration of AGEs in vivo induces extracellular matrix gene expression. Nephrol Dial Transplant. 1996;11 Suppl 5:62-5. doi: https://doi.org/10.1093/ndt/11.supp5.62Li Y, Kang YS, Dai C, et al. Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria. Am J Pathol. 2008 Feb;172(2):299-308. doi: 10.2353/ajpath.2008.070057.Li Y, Kang YS, Dai C, et al. Epithelial-to-mesenchymal transition is a potential pathway leading to podocyte dysfunction and proteinuria. Am J Pathol. 2008;172(2):299-308. doi: https://doi.org/10.2353/ajpath.2008.070057Kumar PA, Welsh GI, Raghu G, et al. Carboxymethyl lysine induces EMT in podocytes through transcription factor ZEB2: Implications for podocyte depletion and proteinuria in diabetes mellitus. Arch Biochem Biophys. 2016 Jan 15;590:10-19. doi: 10.1016/j.abb.2015.11.003.Kumar PA, Welsh GI, Raghu G, et al. Carboxymethyl lysine induces EMT in podocytes through transcription factor ZEB2: Implications for podocyte depletion and proteinuria in diabetes mellitus. Arch Biochem Biophys. 2016;590:10-19. doi: https://doi.org/10.1016/j.abb.2015.11.003Schiffer M, Bitzer M, Roberts IS, et al. Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest. 2001 Sep;108(6):807-16. doi: 10.1172/JCI12367.Schiffer M, Bitzer M, Roberts IS, et al. Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest. 2001;108(6):807-16. doi: https://doi.org/10.1172/JCI12367Bondeva T, Rüster C, Franke S, et al. Advanced glycation end-products suppress neuropilin-1 expression in podocytes. Kidney Int. 2009 Mar;75(6):605-16. doi: 10.1038/ki.2008.603.Bondeva T, Rüster C, Franke S, et al. Advanced glycation end-products suppress neuropilin-1 expression in podocytes. Kidney Int. 2009;75(6):605-16. doi: https://doi.org/10.1038/ki.2008.603López-Díez R, Rastrojo A, Villate O, et al. Complex tissue-specific patterns and distribution of multiple RAGE splice variants in different mammals. Genome Biol Evol. 2013;5(12):2420-35. doi: 10.1093/gbe/evt188.López-Díez R, Rastrojo A, Villate O, et al. Complex tissue-specific patterns and distribution of multiple RAGE splice variants in different mammals. Genome Biol Evol. 2013;5(12):2420-35. doi: https://doi.org/10.1093/gbe/evt188Tam XH, Shiu SW, Leng L, et al. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes. Clin Sci (Lond). 2011 Jan;120(2):81-9. doi: 10.1042/CS20100256.Tam XH, Shiu SW, Leng L, et al. Enhanced expression of receptor for advanced glycation end-products is associated with low circulating soluble isoforms of the receptor in Type 2 diabetes. Clin Sci (Lond). 2011;120(2):81-9. doi: https://doi.org/10.1042/CS20100256Geroldi D, Falcone C, Emanuele E, et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens. 2005 Sep;23(9):1725-9. doi: 10.1097/01.hjh.0000177535.45785.64.Geroldi D, Falcone C, Emanuele E, et al. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J Hypertens. 2005;23(9):1725-9. doi: https://doi.org/10.1097/01.hjh.0000177535.45785.64Prasad K, Mishra M. Do Advanced Glycation End Products and Its Receptor Play a Role in Pathophysiology of Hypertension? Int J Angiol. 2017 Mar;26(1):1-11. doi: 10.1055/s-0037-1598183.Prasad K, Mishra M. Do Advanced Glycation End Products and Its Receptor Play a Role in Pathophysiology of Hypertension? Int J Angiol. 2017;26(1):1-11. doi: https://doi.org/10.1055/s-0037-1598183McNair ED, Wells CR, Qureshi AM, et al. Low levels of soluble receptor for advanced glycation end products in non-ST elevation myocardial infarction patients. Int J Angiol. 2009 Winter;18(4):187-92. doi: 10.1055/s-0031-1278352.McNair ED, Wells CR, Qureshi AM, et al. Low levels of soluble receptor for advanced glycation end products in non-ST elevation myocardial infarction patients. Int J Angiol. 2009;18(4):187-92. doi: https://doi.org/10.1055/s-0031-1278352Basta G, Leonardis D, Mallamaci F, et al. Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. Kidney Int. 2010 Feb;77(3):225-31. doi: 10.1038/ki.2009.419.Basta G, Leonardis D, Mallamaci F, et al. Circulating soluble receptor of advanced glycation end product inversely correlates with atherosclerosis in patients with chronic kidney disease. Kidney Int. 2010;77(3):225-31. doi: https://doi.org/10.1038/ki.2009.419Kalousová M, Hodková M, Kazderová M, et al. Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis. 2006 Mar;47(3):406-11. doi: 10.1053/j.ajkd.2005.12.028.Kalousová M, Hodková M, Kazderová M, et al. Soluble receptor for advanced glycation end products in patients with decreased renal function. Am J Kidney Dis. 2006;47(3):406-11. doi: https://doi.org/10.1053/j.ajkd.2005.12.028Kim JK, Park S, Lee MJ, et al. Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis. Atherosclerosis. 2012 Jan;220(1):208-14. doi: 10.1016/j.atherosclerosis.2011.07.115.Kim JK, Park S, Lee MJ, et al. Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis. Atherosclerosis. 2012;220(1):208-14. doi: https://doi.org/10.1016/j.atherosclerosis.2011.07.115Hartog JW, de Vries AP, Lutgers HL, et al. Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease. Ann N Y Acad Sci. 2005 Jun;1043:299-307. doi: 10.1196/annals.1333.037.Hartog JW, de Vries AP, Lutgers HL, et al. Accumulation of advanced glycation end products, measured as skin autofluorescence, in renal disease. Ann N Y Acad Sci. 2005;1043:299-307. doi: https://doi.org/10.1196/annals.1333.037Renard C, Chappey O, Wautier MP, et al. Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. Mol Pharmacol. 1997 Jul;52(1):54-62. doi: 10.1124/mol.52.1.54.Renard C, Chappey O, Wautier MP, et al. Recombinant advanced glycation end product receptor pharmacokinetics in normal and diabetic rats. Mol Pharmacol. 1997;52(1):54-62. doi: https://doi.org/10.1124/mol.52.1.54Linden E, Cai W, He JC, et al. Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation. Clin J Am Soc Nephrol. 2008 May;3(3):691-8. doi: 10.2215/CJN.04291007.Linden E, Cai W, He JC, et al. Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through RAGE activation. Clin J Am Soc Nephrol. 2008;3(3):691-8. doi: https://doi.org/10.2215/CJN.04291007Isoyama N, Leurs P, Qureshi AR, et al. Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients. Nephrol Dial Transplant. 2015 Jan;30(1):84-91. doi: 10.1093/ndt/gfu259.Isoyama N, Leurs P, Qureshi AR, et al. Plasma S100A12 and soluble receptor of advanced glycation end product levels and mortality in chronic kidney disease Stage 5 patients. Nephrol Dial Transplant. 2015;30(1):84-91. doi: https://doi.org/10.1093/ndt/gfu259Wadén JM, Dahlström EH, Elonen N, et al. Soluble receptor for AGE in diabetic nephropathy and its progression in Finnish individuals with type 1 diabetes. Diabetologia. 2019 Jul;62(7):1268-1274. doi: 10.1007/s00125-019-4883-4.Wadén JM, Dahlström EH, Elonen N, et al. Soluble receptor for AGE in diabetic nephropathy and its progression in Finnish individuals with type 1 diabetes. Diabetologia. 2019;62(7):1268-1274. doi: https://doi.org/10.1007/s00125-019-4883-4Prasad K. Is there any evidence that AGE/sRAGE is a universal biomarker/risk marker for diseases? Mol Cell Biochem. 2019 Jan;451(1-2):139-144. doi: 10.1007/s11010-018-3400-2.Prasad K. Is there any evidence that AGE/sRAGE is a universal biomarker/risk marker for diseases? Mol Cell Biochem. 2019;451(1-2):139-144. doi: https://doi.org/10.1007/s11010-018-3400-2Chiang KH, Chen JW, Huang SS, et al. The ratio of AGE to sRAGE independently associated with albuminuria in hypertensive patients. BMC Endocr Disord. 2018 Nov 13;18(1):84. doi: 10.1186/s12902-018-0306-7.Chiang KH, Chen JW, Huang SS, et al. The ratio of AGE to sRAGE independently associated with albuminuria in hypertensive patients. BMC Endocr Disord. 2018;18(1):84. doi: https://doi.org/10.1186/s12902-018-0306-7Dozio E, Ambrogi F, de Cal M, et al. Role of the Soluble Receptor for Advanced Glycation End Products (sRAGE) as a Prognostic Factor for Mortality in Hemodialysis and Peritoneal Dialysis Patients. Mediators Inflamm. 2018 Oct 15;2018:1347432. doi: 10.1155/2018/1347432.Dozio E, Ambrogi F, de Cal M, et al. Role of the Soluble Receptor for Advanced Glycation End Products (sRAGE) as a Prognostic Factor for Mortality in Hemodialysis and Peritoneal Dialysis Patients. Mediators Inflamm. 2018;2018:1347432. doi: https://doi.org/10.1155/2018/1347432Baragetti I, Norata GD, Sarcina C, et al. -374 T/A RAGE polymorphism is associated with chronic kidney disease progression in subjects affected by nephrocardiovascular disease. PLoS One. 2013 Apr 4;8(4):e60089. doi: 10.1371/journal.pone.0060089.Baragetti I, Norata GD, Sarcina C, et al. -374 T/A RAGE polymorphism is associated with chronic kidney disease progression in subjects affected by nephrocardiovascular disease. PLoS One. 2013;8(4):e60089. doi: https://doi.org/10.1371/journal.pone.0060089Tan AL, Forbes JM, Cooper ME. AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol. 2007 Mar;27(2):130-43. doi: 10.1016/j.semnephrol.2007.01.006.Tan AL, Forbes JM, Cooper ME. AGE, RAGE, and ROS in diabetic nephropathy. Semin Nephrol. 2007;27(2):130-43. doi: https://doi.org/10.1016/j.semnephrol.2007.01.006Ott C, Jacobs K, Haucke E, et al. Role of advanced glycation end products in cellular signaling. Redox Biol. 2014 Jan 9;2:411-29. doi: 10.1016/j.redox.2013.12.016.Ott C, Jacobs K, Haucke E, et al. Role of advanced glycation end products in cellular signaling. Redox Biol. 2014;2:411-29. doi: https://doi.org/10.1016/j.redox.2013.12.016Nakashima A, Carrero JJ, Qureshi AR, et al. Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients. Clin J Am Soc Nephrol. 2010 Dec;5(12):2213-9. doi: 10.2215/CJN.03360410.Nakashima A, Carrero JJ, Qureshi AR, et al. Effect of circulating soluble receptor for advanced glycation end products (sRAGE) and the proinflammatory RAGE ligand (EN-RAGE, S100A12) on mortality in hemodialysis patients. Clin J Am Soc Nephrol. 2010;5(12):2213-9. doi: https://doi.org/10.2215/CJN.03360410Choi BH, Ro H, Jung ES, et al. Circulating S100A12 Levels Are Associated with Progression of Abdominal Aortic Calcification in Hemodialysis Patients. PLoS One. 2016 Feb 25;11(2):e0150145. doi: 10.1371/journal.pone.0150145.Choi BH, Ro H, Jung ES, et al. Circulating S100A12 Levels Are Associated with Progression of Abdominal Aortic Calcification in Hemodialysis Patients. PLoS One. 2016;11(2):e0150145. doi: https://doi.org/10.1371/journal.pone.0150145Yan L, Bjork P, Butuc R, et al. Beneficial effects of quinoline-3-carboxamide (ABR-215757) on atherosclerotic plaque morphology in S100A12 transgenic ApoE null mice. Atherosclerosis. 2013 May;228(1):69-79. doi: 10.1016/j.atherosclerosis.2013.02.023.Yan L, Bjork P, Butuc R, et al. Beneficial effects of quinoline-3-carboxamide (ABR-215757) on atherosclerotic plaque morphology in S100A12 transgenic ApoE null mice. Atherosclerosis. 2013;228(1):69-79. doi: https://doi.org/10.1016/j.atherosclerosis.2013.02.023Ishibashi Y, Yamagishi S, Matsui T, et al. Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level. Metabolism. 2012 Aug;61(8):1067-72. doi: 10.1016/j.metabol.2012.01.006.Rahbar S, Natarajan R, Yerneni K, et al. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin Chim Acta. 2000;301(1-2):65-77. doi: https://doi.org/10.1016/s0009-8981(00)00327-2Xu L, Zang P, Feng B, et al. Atorvastatin inhibits the expression of RAGE induced by advanced glycation end products on aortas in healthy Sprague-Dawley rats. Diabetol Metab Syndr. 2014 Sep 23;6(1):102. doi: 10.1186/1758-5996-6-102.Kanazawa I, Yamamoto M, Yamaguchi T, et al. Effects of metformin and pioglitazone on serum pentosidine levels in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2011;119(6):362-5. doi: https://doi.org/10.1055/s-0030-1267953Okamoto T, Yamagishi S, Inagaki Y, et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J. 2002 Dec;16(14):1928-30. doi: 10.1096/fj.02-0030fje.Zhang SS, Wu Z, Zhang Z, Xiong ZY, Chen H, Huang QB. Glucagon-like peptide-1 inhibits the receptor for advanced glycation endproducts to prevent podocyte apoptosis induced by advanced oxidative protein products. Biochem Biophys Res Commun. 2017;482(4):1413-1419. doi: https://doi.org/10.1016/j.bbrc.2016.12.050Forbes JM, Cooper ME, Thallas V, et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes. 2002 Nov;51(11):3274-82. doi: 10.2337/diabetes.51.11.3274.Forbes JM, Cooper ME, Thallas V, et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes. 2002;51(11):3274-82. doi: https://doi.org/10.2337/diabetes.51.11.3274Rahbar S, Natarajan R, Yerneni K, et al. Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. Clin Chim Acta. 2000 Nov;301(1-2):65-77. doi: 10.1016/s0009-8981(00)00327-2.Ishibashi Y, Yamagishi S, Matsui T, et al. Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level. Metabolism. 2012;61(8):1067-72. doi: https://doi.org/10.1016/j.metabol.2012.01.006Kanazawa I, Yamamoto M, Yamaguchi T, et al. Effects of metformin and pioglitazone on serum pentosidine levels in type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes. 2011 Jun;119(6):362-5. doi: 10.1055/s-0030-1267953.Xu L, Zang P, Feng B, et al. Atorvastatin inhibits the expression of RAGE induced by advanced glycation end products on aortas in healthy Sprague-Dawley rats. Diabetol Metab Syndr. 2014;6(1):102. doi: https://doi.org/10.1186/1758-5996-6-102Sung JY, Chung W, Kim AJ, et al. Calcitriol treatment increases serum levels of the soluble receptor of advanced glycation end products in hemodialysis patients with secondary hyperparathyroidism. Tohoku J Exp Med. 2013 May;230(1):59-66. doi: 10.1620/tjem.230.59.Okamoto T, Yamagishi S, Inagaki Y, et al. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J. 2002;16(14):1928-30. doi: https://doi.org/10.1096/fj.02-0030fjeVlassara H, Uribarri J, Cai W, et al. Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin J Am Soc Nephrol. 2012 Jun;7(6):934-42. doi: 10.2215/CJN.12891211.Sung JY, Chung W, Kim AJ, et al. Calcitriol treatment increases serum levels of the soluble receptor of advanced glycation end products in hemodialysis patients with secondary hyperparathyroidism. Tohoku J Exp Med. 2013;230(1):59-66. doi: https://doi.org/10.1620/tjem.230.59Huang K, Huang J, Xie X, et al. Sirt1 resists advanced glycation end products-induced expressions of fibronectin and TGF-β1 by activating the Nrf2/ARE pathway in glomerular mesangial cells. Free Radic Biol Med. 2013 Dec;65:528-540. doi: 10.1016/j.freeradbiomed.2013.07.029.Vlassara H, Uribarri J, Cai W, et al. Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin J Am Soc Nephrol. 2012;7(6):934-42. doi: https://doi.org/10.2215/CJN.12891211Hong Q, Zhang L, Das B, et al. Increased podocyte Sirtuin-1 function attenuates diabetic kidney injury. Kidney Int. 2018 Jun;93(6):1330-1343. doi: 10.1016/j.kint.2017.12.008.Huang K, Huang J, Xie X, et al. Sirt1 resists advanced glycation end products-induced expressions of fibronectin and TGF-β1 by activating the Nrf2/ARE pathway in glomerular mesangial cells. Free Radic Biol Med. 2013;65:528-540. doi: https://doi.org/10.1016/j.freeradbiomed.2013.07.029Matsui T, Higashimoto Y, Nishino Y, et al. RAGE-Aptamer Blocks the Development and Progression of Experimental Diabetic Nephropathy. Diabetes. 2017 Jun;66(6):1683-1695. doi: 10.2337/db16-1281.Hong Q, Zhang L, Das B, et al. Increased podocyte Sirtuin-1 function attenuates diabetic kidney injury. Kidney Int. 2018;93(6):1330-1343. doi: https://doi.org/10.1016/j.kint.2017.12.008Candido R, Forbes JM, Thomas MC, et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res. 2003 Apr 18;92(7):785-92. doi: 10.1161/01.RES.0000065620.39919.20.Matsui T, Higashimoto Y, Nishino Y, et al. RAGE-Aptamer Blocks the Development and Progression of Experimental Diabetic Nephropathy. Diabetes. 2017;66(6):1683-1695. doi: https://doi.org/10.2337/db16-1281Candido R, Forbes JM, Thomas MC, et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res. 2003;92(7):785-92. doi: https://doi.org/10.1161/01.RES.0000065620.39919.20Candido R, Forbes JM, Thomas MC, et al. A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes. Circ Res. 2003;92(7):785-92. doi: https://doi.org/10.1161/01.RES.0000065620.39919.20

The authors declare that there are no conflicts of interest present.